Published in Lab Law Weekly, August 27th, 2004
Celera Genomics Group (CRA), an Applera Corp. business, reported a net loss of $5.8 million, or $0.08 per share, for the fourth quarter of fiscal 2004 ended June 30, 2004, compared to a net loss of $19.4 million, or $0.27 per share, for the fourth quarter of fiscal 2003.
The fourth-quarter fiscal-2004 results included a $24.8 million pretax gain associated with the sale of the company's investment in Discovery Partners International, Inc., (DPII) and a non-cash pretax charge of $18.1 million, representing the estimated loss on the planned sale of Celera Genomics' Rockville, Maryland facility. These items reduced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.